Abstract
As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. We report updated meta-analyses of the trials of 5 years of adjuvant tamoxifen. We undertook a collaborative meta-analysis of individual patient data from 20 trials (n=21 457) in early breast cancer of about 5 years of tamoxifen versus no adjuvant tamoxifen, with about 80% compliance. Recurrence and death rate ratios (RRs) were from log-rank analyses by allocated treatment.
Original language | English |
---|---|
Pages (from-to) | 771-784 |
Number of pages | 14 |
Journal | Lancet |
Volume | 378 |
Issue number | 9793 |
Early online date | 29 Jul 2011 |
DOIs | |
Publication status | Published - Aug 2011 |
Keywords
- breast cancer
- hormone receptors
- tamoxifen
- randomised trials